Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606345 | 1.00 | EPHX1 (0.40) | EPHX1CYP19A1NAAAHTTTSHR | |
| SCHEMBL5986431 | 1.00 | EPHX1 (0.40) | EPHX1CYP19A1NAAAHTTTSHR | |
| SCHEMBL7604345 | 0.95 | TSHR (0.37) | EPHX1CYP19A1NAAAHTTTSHR | |
| SCHEMBL5987693 | 0.95 | TSHR (0.37) | EPHX1CYP19A1NAAAHTTTSHR | |
| SCHEMBL5987796 | 0.95 | TSHR (0.37) | EPHX1CYP19A1NAAAHTTTSHR | |
| SCHEMBL16312681 | 0.86 | EPHX1 (0.38) | EPHX1CYP19A1NAAAHTTTSHR | |
| SCHEMBL7371640 | 0.84 | EPHX1 (0.39) | EPHX1CYP19A1NAAAHTTTSHR | |
| SCHEMBL7371636 | 0.84 | EPHX1 (0.39) | EPHX1CYP19A1NAAAHTTTSHR | |
| SCHEMBL13647263 | 0.84 | CYP19A1 (0.41) | EPHX1CYP19A1NAAAHTTTSHR | |
| SCHEMBL13130088 | 0.84 | EPHX1 (0.41) | EPHX1CYP19A1NAAAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-2447264-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | REN, AGTR1, AGTR2 | EPHX1 2234/4885CYP19A1 397/4885NAAA 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.